Curated news and analysis on clinical trials, drug approvals, and medical research.
The phase 3 AMPLIFY trial in frontline chronic lymphocytic leukemia showed improved efficacy with acalabrutinib plus venetoclax versus standard of care. The source text identified the study as NCT03836261.
The FDA cleared MiniMed Flex, a screen-free insulin pump controlled by smartphone, and granted breakthrough device designation to Portal Diabetes’ implantable Portal Pump system. Portal Diabetes also began a Phase I study of Portal Insulin, while MiniMed said Flex supports its latest algorithm, sensors and infusion sets.
University of Missouri researchers released PSBench, a database of 1.4 million annotated protein structure models verified by independent experts. The resource aims to improve AI assessment of protein models as biologic drug discovery moves toward data-driven design.
ARVO named Sangeetha Kandoi and Ellen Konadu Antwi-Adjei as the 2026 recipients of its annual Advocacy Awards. The honors recognize advocacy in eye and vision research and efforts to expand equitable access to care.
The FDA reminded more than 2,200 sponsors and researchers to submit required clinical trial results and said 29.6% of likely reportable studies lacked posted results. It also issued warning letters over CGMP violations at a contract manufacturer and protocol failures that led to excessive dosing in a clinical study.
PharmaMar and Globant deployed a multi-agent AI framework to accelerate oncology drug discovery. The system delivers over 90% accuracy in data retrieval and generates insights up to 15 times faster.
Arecor said it is in talks on a broader AT278 partnership as it targets a phase II trial start in the second half of 2026. The company also cited FDA feedback, Ligand financing and year-end cash of £6.1 million.
China’s cross-border biotech outlicensing hit US$60 billion in the first quarter of 2026. AbbVie’s up to $745 million Haisco pain deal highlights multinationals’ rising interest in Chinese drug assets.
Bristol Myers Squibb started a Phase 1 trial of BMS-986506 in clear cell renal cell carcinoma, triggering a $10 million milestone payment to Evotec SE. The candidate is the first molecular glue from the companies’ protein-degradation partnership to enter human testing.
The FDA has cleared the Onclarity HPV Self-Collection Kit for at-home use, with availability by prescription expected in the coming months. A JAMA Network Open study found 61% of women still prefer clinic screening, while 20% prefer self-sampling at home.
The healthcare 3D printing market is projected to reach $14.6 billion by 2033, while the bioinks market is anticipated to reach USD 683.6 million. Growth is tied to personalised medical solutions, tissue engineering, drug discovery, and advances in biomaterials.
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
A retrospective review found tisotumab vedotin produced similar response rates in radiated and non-radiated cervical cancer lesions. In the 29-patient cohort, median overall survival was 11.0 months and median progression-free survival was 2.8 months.
A high-throughput screen of 20,000 compounds identified four compounds with novel antifungal activity against Candida albicans. Z56842335 cleared infection in a Galleria mellonella model and showed a metal-dependent mode of action.
New findings on psychedelic-based depression treatments included a UK DMT trial in 34 adults and a mouse study of modified psilocin compounds with fewer hallucinogenic-like effects.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Generative AI processed complex medical datasets faster than traditional teams in a preterm birth study, while the healthcare market for the technology reached US$2.92 billion in 2024. The market is projected to grow to US$30.68 billion by 2033 as adoption expands in clinical workflows, imaging, drug discovery and precision medicine.
Puma Biotechnology reported quarterly revenue of $75.50 million and EPS of $0.26, above consensus estimates. The company also guided for 2026 total revenue of US$214 million to US$221 million and net income of US$10 million to US$13 million.
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
